Prexton News

Prexton Acquired by Lundbeck for up to €905m

16th March 2018

Oss, The Netherlands & Dublin, Ireland, 16 March 2018 – H. Lundbeck A/S (Lundbeck) and Seroba’s Investee Company, Prexton Therapeutics BV (Prexton), today announced the signing of a definitive agreement in which Lundbeck will acquire Prexton. Under the terms of […]

Read More
Prexton News

Prexton announces clinical testing in Parkinson’s disease

10th July 2017

Seroba’s investee company, Prexton Therapeutics (Prexton), a biopharma company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, today announces the launch of phase II clinical testing of its investigational drug candidate, Foliglurax, in Parkinson’s disease […]

Read More
Prexton News

Prexton Therapeutics Series B financing round raises €29 million

17th February 2017

Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic.  Forbion & Seroba co-led the funding, forming an international consortium with Merck Ventures, Ysios and Sunstone.  Funding to finance two Phase II trials in Parkinson’s disease. Geneva, […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19

Scroll to Top